Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group..

Am J Geriatr Psychiatry. 2010 Apr;18(4):332-40. doi: 10.1097/JGP.0b013e3181cc0333.

2.

A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project.

McHugh GS, Butcher I, Steyerberg EW, Marmarou A, Lu J, Lingsma HF, Weir J, Maas AI, Murray GD.

Clin Trials. 2010 Feb;7(1):44-57. doi: 10.1177/1740774509356580.

PMID:
20156956
3.

Management of behavioral problems in Alzheimer's disease.

Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C.

Int Psychogeriatr. 2010 May;22(3):346-72. doi: 10.1017/S1041610209991505. Review.

PMID:
20096151
4.

Sertraline for the treatment of depression in Alzheimer disease.

Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group..

Am J Geriatr Psychiatry. 2010 Feb;18(2):136-45. doi: 10.1097/JGP.0b013e3181c796eb.

5.

Anticonvulsants in the treatment of aggression in the demented elderly: an update.

Amann B, Pantel J, Grunze H, Vieta E, Colom F, Gonzalez-Pinto A, Naber D, Hampel H.

Clin Pract Epidemiol Ment Health. 2009 Jun 16;5:14. doi: 10.1186/1745-0179-5-14.

6.

Management of agitation and aggression associated with Alzheimer disease.

Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG.

Nat Rev Neurol. 2009 May;5(5):245-55. doi: 10.1038/nrneurol.2009.39. Review.

PMID:
19488082
7.

Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities.

Simoni-Wastila L, Ryder PT, Qian J, Zuckerman IH, Shaffer T, Zhao L.

Am J Geriatr Psychiatry. 2009 May;17(5):417-27. doi: 10.1097/JGP.0b013e31819b8936.

8.

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R; DART-AD investigators..

Lancet Neurol. 2009 Feb;8(2):151-7. doi: 10.1016/S1474-4422(08)70295-3.

PMID:
19138567
9.

Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease.

Ueki A, Ueno H, Sato N, Shinjo H, Morita Y.

J Alzheimers Dis. 2007 Nov;12(3):245-53.

PMID:
18057558
10.

A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.

Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, Huber KA.

Am J Geriatr Psychiatry. 2007 Nov;15(11):942-52.

PMID:
17846102
11.

Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study.

Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, Breitner JC, Steffens DC, Tschanz JT; Cache County Investigators..

Int J Geriatr Psychiatry. 2008 Feb;23(2):170-7.

12.

A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease.

Lanctôt KL, Hussey DF, Herrmann N, Black SE, Rusjan PM, Wilson AA, Houle S, Kozloff N, Verhoeff NP, Kapur S.

Am J Geriatr Psychiatry. 2007 Oct;15(10):888-98.

PMID:
17567932
13.

Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study.

Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkälä KH.

Am J Geriatr Psychiatry. 2007 May;15(5):416-24.

PMID:
17463191
14.

Design of Depression in Alzheimer's Disease Study-2.

Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Niederehe G, Lyketsos CG.

Am J Geriatr Psychiatry. 2006 Nov;14(11):920-30.

PMID:
17068314
15.

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group..

N Engl J Med. 2006 Oct 12;355(15):1525-38.

16.

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

Lyketsos CG, Colenda CC, Beck C, Blank K, Doraiswamy MP, Kalunian DA, Yaffe K; Task Force of American Association for Geriatric Psychiatry..

Am J Geriatr Psychiatry. 2006 Jul;14(7):561-72. No abstract available. Erratum in: Am J Geriatr Psychiatry. 2006 Sep;14(9):808.

PMID:
16816009
17.

Neuroleptic drugs in dementia: benefits and harm.

Ballard C, Howard R.

Nat Rev Neurosci. 2006 Jun;7(6):492-500. Review.

PMID:
16715057
18.
19.

Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA.

N Engl J Med. 2005 Dec 1;353(22):2335-41.

20.

Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study.

Ryu SH, Katona C, Rive B, Livingston G.

Am J Geriatr Psychiatry. 2005 Nov;13(11):976-83.

PMID:
16286441
Items per page

Supplemental Content

Support Center